Blogs

Many of us have failed to place a name with a familiar face, struggled to concentrate during a long lecture, or misplaced the car keys, but for cancer patients undergoing treatment, this cognitive impairment can happen all too frequently and impact   (Read More)

A recent study conducted by researchers at the University of Oklahoma Health Sciences Center revealed that nearly 90% of American adults have inadequate knowledge of palliative care. Why is there a tremendous knowledge gap about a healthcare service   (Read More)

Like 90% of women who receive a normal mammogram result each year, Cheryl Wilde breathed a huge sigh of relief when she was told her results were clear. Yet, although she received what she thought was excellent news that day in 1994, her breast   (Read More)

The 2017 FDA approval of Keytruda for patients whose cancers have specific genetic features was the first time the agency approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor began to grow.   (Read More)

Ovarian cancer awareness remains on the forefront of the minds of OHC’s cancer specialists. Ovarian cancer is most often diagnosed in its late stages as its presenting symptoms are typically subtle and sometimes mistaken for more common conditions.   (Read More)

With an enduring interest in offering hope to patients with aggressive cancers, OHC participated in a clinical trial that recently resulted in the FDA approval of a new breast cancer treatment. To help develop new treatment options for   (Read More)

Imagine going to the doctor with some abdominal pain. You’re not expecting the worst. Appendicitis and a hernia are ruled out and a blood test and chest X-ray are ordered. Upon receiving additional test results, your doctor immediately admits you   (Read More)

In its relentless pursuit of the newest and most innovative cancer treatments, OHC has recently played a role in three new FDA approved therapies. On August 10, the FDA approved Lenvima (lenvatnib) plus Keytruda (pembrolizumab) for adults with   (Read More)

Last week, Cancer Family Care (CFC) hosted its 19th annual Joslin Haggart Yeiser Unsung Hero Awards to honor patients, caregivers, and oncology professionals who quietly change the lives of those living with cancer. The event recognized 2020 heroes   (Read More)

Karen Herzog, an ovarian cancer survivor, knows all too well what it’s like to cope with cancer during treatment. She was a patient of OHC’s Cynthia C. Chua, MD, and Sarah Wilson, MSN, APRN. It wasn’t long after she completed her chemotherapy   (Read More)

OHC is part of the nation’s largest research network specializing in oncology clinical trials, US Oncology Research, which has played a role in more than 100 FDA approved cancer therapies. OHC’s pioneers in research continue to lead in cancer   (Read More)

When David Shellabarger went to his doctor because he was experiencing stomach pain, he didn’t expect a cancer diagnosis. “I thought I had a hernia,” said David. “My CT scan and biopsy revealed non-Hodgkin lymphoma.” That was August of   (Read More)

In Lake County, Florida sits a community clubhouse where the Little Lake Harris Quilters gather for their Monday morning meetings. The group’s members are snowbirds who are skilled in both quilting and embroidery, often raffling off their   (Read More)

Watching Brant Karrick teach his music students at Northern Kentucky University (NKU), one would never know that he suffered from both Hodgkin’s lymphoma and MDS, a bone marrow disorder. During one of his final Ensemble Chamber Winds courses of the   (Read More)

Sarcoma is often referred to as the “forgotten cancer,” most likely because it comprises less than one percent of all adult cancers. During this Sarcoma Awareness Month, OHC’s cancer experts believe it is important to bring awareness to this   (Read More)